Hubei Jianxiang secures approval for Leuprorelin Acetate API

Sichuan Harmonious Shuangma Co., Ltd. announced its controlled subsidiary, Hubei Jianxiang Biological Pharmaceutical Co., Ltd., has received marketing approval for Leuprorelin Acetate as an active pharmaceutical ingredient (API). The approval, issued by China's National Medical Products Administration, signifies the product meets pharmaceutical registration requirements and can now be produced and sold in the domestic market.

The approved API, with registration number Y20240000206, is packaged in 50g/bottle/bag. Leuprorelin Acetate is a gonadotropin-releasing hormone (GnRH) agonist, used to treat conditions such as endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty.

This approval enriches Hubei Jianxiang's product line and strengthens the company's competitive position in the specialized API sector within China. The company cautioned investors that the pharmaceutical industry is subject to market conditions, industry policies, and supply-demand fluctuations, leading to inherent uncertainties in product production and sales.